Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Breast Cancer Trial Results

  • Radiation Therapy after Breast-Conserving Surgery Improves Survival
    (Posted: 12/02/2011) - Radiation therapy after breast-conserving surgery substantially reduces the risk of cancer recurring in the breast and moderately reduces the risk of death from the disease, according to updated results from a meta-analysis by the Early Breast Cancer Trialists' Collaborative Group.
  • Study Confirms Letrozole Prevents More Breast Cancer Recurrences than Tamoxifen
    (Posted: 12/02/2011) - After a median of 8 years of follow-up from a large randomized trial, women with estrogen-receptor positive breast cancer who received 5 years of treatment with letrozole were less likely to have their cancer recur or to die during follow-up than women who had 5 years of treatment with tamoxifen.
  • Long-Term Data from 20 Trials Confirm Tamoxifen’s Long-Lasting Benefit
    (Posted: 11/23/2011) - In an analysis of data from participants in 20 clinical trials, women with estrogen receptor-positive breast cancer who received about 5 years of adjuvant treatment with tamoxifen had a lower risk of recurrence in the 15 years after starting treatment than women who did not receive tamoxifen.
  • Chemotherapy Less Toxic to the Heart May Be Option for Some Women with HER2-Positive Breast Cancer
    (Posted: 11/03/2011) - A nonanthracycline-containing chemotherapy regimen combined with the targeted therapy trastuzumab may be an option for some women with HER2-positive breast cancer, according to results from the Breast Cancer International Research Group 006 (BCIRG-006) trial reported October 6, 2011, in the New England Journal of Medicine.
  • Zoledronic Acid Did Not Improve Disease-Free Survival in Breast Cancer
    (Posted: 12/27/2010, Updated: 10/20/2011) - The addition of zoledronic acid to standard adjuvant therapy did not extend disease-free survival for women with stage II or III breast cancer in the phase III AZURE trial, results of which were presented at the 2010 San Antonio Breast Cancer Symposium.
< Previous  1 2 3 4 5  Next >